Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.

Journal of cancer research and clinical oncology - 1 Jan 2011

Pan Li, Peng Xing-Chen, Leng Fei, Yuan Qing-Zhong, Shan Yan, Yu Dan-Dan, Li Zhi-Yong, Chen Xiang, Xiao Wen-Jing, Wen Yuan, Ma Tian-Tai, Yang Li, Mao Yong-Qiu, Yang Han-Shuo, Wei Yu-Quan, Wang Chun-Ting

Abstract excerpt

PURPOSE: Patients with localized prostate cancer can usually achieve initial response to conventional treatment. However, most of them will inevitably progress to advanced disease stage. There is a clear need to develop innovative and effective therapeutics for prostate cancer. Mouse survivin T34A (mS-T34A) is a phosphorylation-defective Thr34 → Ala dominant negative mutant, which represents a potential promising...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fatty Acids, Monounsaturated
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitor of Apoptosis Proteins

Share to Liposomes

Share to Microscopy, Fluorescence

Share to Prostatic Neoplasms

Share to Quaternary Ammonium Compounds

Share to Survivin

Source

Identifiers

PMID: 20217127
DOI: 10.1007/s00432-010-0855-2

Genes

MVD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.PMID 20217127Read ↗

Inhibition of lymphatic metastases by a survivin dominant-negative mutant.Semantic proximity Read ↗

rAAV-Delivered PTEN Therapeutics for Prostate CancerSemantic proximity Read ↗

Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.Semantic proximity Read ↗

Targeting Gene‐ViroTherapy for prostate cancer by DD3‐driven oncolytic virus‐harboring interleukin‐24 geneSemantic proximity Read ↗

Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivoSemantic proximity Read ↗

Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer GrowthSemantic proximity Read ↗

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancerSemantic proximity Read ↗

Transgenic construction and functional miRNA analysis identify the role of miR-7 in prostate cancer suppressionSemantic proximity Read ↗

Boosting the Immune Response – Combining the Local and Immune Therapy for Prostate Cancer TreatmentSemantic proximity Read ↗

CRISPR-Cas9 genome engineering as a novel prognostic tools for Prostate cancer: long non-coding RNAs the predictive diagnostic index of targeted liposomal-coated compounds in prostate cancer therapySemantic proximity Read ↗

A survivin-driven tumour-activatable minicircle system for prostate cancer theranosticsSemantic proximity Read ↗

A Black Phosphorus Nanosheet-based RNA Delivery System for Prostate Cancer Therapy by Increasing the Expression Level of Tumor Suppressor Gene PTEN via CeRNA MechanismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.